Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials

Figure 1 Flow diagram of studies identified and selected.

Figure 2 Risk of pancreatic adverse events in patients treated with glucagon-like peptide-1 based therapies (A and B).

Figure 3 Risk of pancreatitis in patients treated with glucagon-like peptide-1 based therapies (A and B).

Figure 4 Risk of elevated pancreatic enzymes for glucagon-like peptide-1 based agents.

Figure 5 Risk of pancreatic events for glucagon-like peptide-1 receptor agonist drugs only.

Figure 6 Funnel plot for risk of pancreatic adverse events.